feed
view company updates
tools
perform investment research
network
join events & discussions
advisory
about us
Redeye Capital
Orexo: Zubsolv Rx data
Research Update
2019-11-08
15:49
The Zubsolv market share was unchanged in October, amounting to 4.5% (quantity). This development was in/line with our expectations.
KP
Klas Palin
Disclosures and disclaimers
Premium Plan required to unlock
Unlock companies to access
more high quality research.
View Plans